 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN has begun treating the first patient in the phase I study of its lead asset. SLN124 is being developed for the treatment of types of anaemia, the blood disorder thalassemia and myelodysplastic syndrome, a form of cancer. 